Allogene Therapeutics
Yuan Lin is a Principal Scientist at Allogene Therapeutics since June 2022, with previous experience as a Senior Scientist at Bristol Myers Squibb and a Staff Scientist at Thermo Fisher Scientific. Yuan has significant expertise in the development and analysis of single-cell gene expression profiling related to drug resistance in breast cancer, as well as the characterization of tumor-initiating cells in various models. Prior roles include postdoctoral positions at BioVision and Stanford University, where Yuan focused on gene transfer in hematopoietic stem cells and conducted research on tumor biology. Yuan's academic background includes a PhD in Molecular Virology from Case Western Reserve University, complemented by a Master's degree in Traditional Chinese Medicine and a Bachelor's degree in Biology. Early career experience includes roles at Clontech involving DNA microarray production and quality control.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.